U.S. Markets closed

Zynerba Pharmaceuticals, Inc. (ZYNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.2200-0.0800 (-1.86%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.3000
Open4.3000
Bid4.1000 x 900
Ask4.2900 x 1800
Day's Range4.1200 - 4.3300
52 Week Range2.5500 - 12.5100
Volume541,988
Avg. Volume1,838,179
Market Cap105.292M
Beta (5Y Monthly)3.07
PE Ratio (TTM)N/A
EPS (TTM)-1.5720
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • GlobeNewswire

    Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference

    DEVON, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the virtual 40th Annual Canaccord Genuity Growth Conference. The presentation will take place on Wednesday, August 12, 2020 at 4:30PM EDT. This meeting is being held virtually, and a live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com.About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.  Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations.  These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.Investor Contact William Roberts, Vice President, Investor Relations and Corporate Communications Zynerba Pharmaceuticals 484.581.7489 robertsw@zynerba.com

  • Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know

    Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $3.79, moving +1.34% from the previous trading session.

  • What's in the Cards for Zynerba (ZYNE) This Earnings Season?
    Zacks

    What's in the Cards for Zynerba (ZYNE) This Earnings Season?

    Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.